Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D, but the benefits are years away and the risks are immediate. Eylea franchise revenues dropped 26% year-over-year as ...

In the first quarter of 2025, Regeneron faced headwinds, particularly with its Eylea franchise. The company reported a challenging period, with Eylea sales missing consensus expectations due to ...

Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), a leading biopharmaceutical company with a market capitalization of $62.17 billion, finds itself at a critical juncture as it navigates challenges to its ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Chicago, IL – June 10, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva Pharmaceuticals TEVA and Viatris VTRS ...